62667-25-8

Basic information

• Product Name: BENZOOXAZOLE-2-CARBALDEHYDE
• Synonyms: BENZO[D]OXAZOLE-2-CARBALDEHYDE;BENZOOXAZOLE-2-CARBALDEHYDE;RARECHEM AK ML 0183;2-Benzoxazolecarboxaldehyde (6CI, 9CI);2-Benzoxazolecarboxaldehyde
• CAS NO: 62667-25-8
• Molecular Formula: C₈H₅NO₂
• Molecular Weight: 147.13
• Product Categories: ALDEHYDE
• Mol File: 62667-25-8.mol
• Article Data: 11

Chemical Properties

• Boiling Point: 276.3 °C at 760 mmHg
• Flash Point: 120.9 °C
• Appearance: /
• Density: 1.322 g/cm³
• Storage Temp.: Inert atmosphere,Store in freezer, under -20°C
• PKA: 0.17±0.10(Predicted)
• CAS DataBase Reference: BENZOOXAZOLE-2-CARBALDEHYDE(CAS DataBase Reference)
• NIST Chemistry Reference: BENZOOXAZOLE-2-CARBALDEHYDE(62667-25-8)
• EPA Substance Registry System: BENZOOXAZOLE-2-CARBALDEHYDE(62667-25-8)

Safety Data

• Hazardous Substances Data: 62667-25-8(Hazardous Substances Data)

Upstream product

• 95-21-6 2-methyl-1,3-benzoxazole 
• 80352-44-9 1-benzooxazol-2-ylmethyl-pyridinium; iodide 
• 27383-86-4 benzoxazole-2-carboxylic acid methyl ester 
• 4637-24-5 N,N-dimethyl-formamide dimethyl acetal 
• 614-80-2 2-(acetylamino)phenol 
• 95-55-6 2-amino-phenol 

Downstream Products

• 68700-43-6 4-benzooxazol-2-ylmethylene-2-(2,4-dinitro-phenyl)-5-methyl-2,4-dihydro-pyrazol-3-one 
• 68748-40-3 2-(4-benzooxazol-2-ylmethylene-5-methyl-2-phenyl-2,4-dihydro-pyrazol-3-ylidenemethyl)-1-ethyl-pyridinium; iodide 
• 68700-31-2 2-(4-benzooxazol-2-ylmethylene-5-methyl-2-phenyl-2,4-dihydro-pyrazol-3-ylidenemethyl)-1-ethyl-quinolinium; iodide 
• 68700-32-3 2-(4-benzooxazol-2-ylmethylene-5-methyl-2-phenyl-2,4-dihydro-pyrazol-3-ylidenemethyl)-3-ethyl-benzooxazolium; iodide 
• 68700-33-4 2-[4-benzooxazol-2-ylmethylene-2-(2,4-dinitro-phenyl)-5-methyl-2,4-dihydro-pyrazol-3-ylidenemethyl]-1-ethyl-pyridinium; iodide 
• 68700-34-5 2-[4-benzooxazol-2-ylmethylene-2-(2,4-dinitro-phenyl)-5-methyl-2,4-dihydro-pyrazol-3-ylidenemethyl]-1-ethyl-quinolinium; iodide 
• 68700-36-7 2-[4-benzooxazol-2-ylmethylene-2-(2,4-dinitro-phenyl)-5-methyl-2,4-dihydro-pyrazol-3-ylidenemethyl]-3-ethyl-benzooxazolium; iodide 
• 1402598-34-8 N-(1,3-benzoxazol-2-yl(phenyl)methyl)-3,4-dihydro-2H-1,5-benzodioxepine-7-sulfonamide 
• 1426083-10-4 C₂₂H₁₅N₃O₄S 
• 28458-93-7 benzo[d]oxazol-2-yl(phenyl)methanone 
• 1426082-76-9 (benzoxazol-2-yl)(3-methylphenyl)methanone 
• 1258498-75-7 benzo[d]oxazol-2-yl(4-methoxy phenyl)methanone 
• 1327274-44-1 benzo[d]oxazol-2-yl(3-bromophenyl)methanone 
• 1258498-71-3 benzo[d]oxazol-2-yl(o-tolyl)methanone 

Relevant articles and documents

Iodine-catalyzed oxidative annulation: Facile synthesis of pyrazolooxepinopyrazolones: Via methyl azaarene sp3C-H functionalization

An iodine-catalyzed methyl azaarene sp3 C-H functionalization has been developed for the synthesis of a seven-membered O-heterocyclic architecture containing three different heterocyclic aromatic hydrocarbons. This method can be applied to a wide range of substituted methyl azaarenes and diverse 2,4-dihydro-3H-pyrazol-3-ones, and brings about the efficient preparation of 2,9-dihydrooxepino[2,3-c:6,5-c′]dipyrazol-3(7H)-ones in high yields with the merits of low catalyst loading, good functional group tolerance and metal-free conditions.

CIS CINNAMIC ACID ANALOG AND GRAVITROPISM MODIFIER

PROBLEM TO BE SOLVED: To provide a gravitropism modifier having effects on creeping property of plants or sugar content of fruits. SOLUTION: There is provided a gravitropism modifier containing cis cinnamic acid and/or a cinnamic acid analog represented by the formula (1) as active ingredients. (1), where A is cyclic hydrocarbon which may have a substituent, X is a bound or a C1 to 5 substituted or unsubstituted hydrocarbon chain, R1 is H, a hydroxyl group, an alkali earth metal salt or the like, R2 is a bond or a C1 to 5 substituted or unsubstituted hydrocarbon chain and R3 and R4 are H or together form C5 to 8 cyclic hydrocarbon. SELECTED DRAWING: Figure 6 COPYRIGHT: (C)2016,JPOandINPIT

LRRK2 INHIBITORS

Provided herein are compounds that inhibit or partially inhibit the activity of leucine rich repeat kinases. Also provided herein are methods of treatment of CNS disorders comprising administration of inhibitors of leucine rich repeat kinases.